What Predicine does

Predicine is a private molecular diagnostics company founded in 2015 and headquartered in Hayward, California, with 101-250 employees and a stated workforce composition of approximately 35% PhDs. The company develops liquid biopsy–based genomic profiling assays for cancer diagnostics, treatment selection, monitoring, and minimal residual disease (MRD) detection, serving two primary customer bases: biopharmaceutical companies (for biomarker-driven clinical trial support and companion diagnostic co-development) and licensed physicians/healthcare providers (for clinical diagnostic testing).

Its core technology is the proprietary GeneRADAR platform, which performs simultaneous cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling from a single blood or urine sample, paired with the DeepSEA bioinformatics pipeline that uses proprietary analytical methods to suppress sequencing/PCR error and call variants at ultra-sensitive levels (down to 5 PPM for MRD and as little as 0.4 mL of plasma input). The commercial product portfolio includes PredicineBEACON (personalized MRD), PredicineATLAS (600-gene pan-cancer panel), PredicineCARE (200-gene treatment selection assay under FDA PMA review), PredicineRNA (88-gene fusion/splicing panel), PredicineHEME (259-gene hematologic panel), PredicineWES+ (exome sequencing), and PredicineHEREDITARY (25-gene germline assay), supplemented by add-on modules (PredicineCARE Ultra, PredicineALERT, PredicineSCORE).

Predicine monetizes through (i) fee-for-service clinical laboratory testing performed in its CAP/CLIA-certified labs (5 facilities across Hayward CA, Houston TX, Schaumburg IL, and Shanghai), (ii) biopharma professional services contracts spanning biomarker discovery through Phase I-III clinical trial support, and (iii) a future companion diagnostic licensing/royalty stream contingent on FDA approval of PredicineCARE (PMA module submitted September 2025; Breakthrough Device Designation granted 2022). Go-to-market is enterprise field sales to biopharma combined with physician-driven test ordering, scientific conference presence (ASCO, AACR, ASCO GU), peer-reviewed publication strategy, and regional distribution partners (zakara, daladria, CellDiagnostics, sciencewerke). Pricing is not publicly disclosed.

Name

Predicine

Legal name

Predicine, Inc.

Website

https://predicine.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Predicine is a molecular diagnostics company that develops liquid biopsy genomic profiling assays for cancer treatment selection, monitoring, and MRD detection, serving biopharmaceutical companies, physicians, and academic researchers through CAP/CLIA-certified labs in the US and China.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Liquid Biopsy Cancer Genomics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industry

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)

Keywords

• Liquid biopsy diagnostics
• Cancer genomic profiling
• Next-generation sequencing
• Companion diagnostics
• Minimal residual disease monitoring

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: Predicine generates revenue through providing CLIA-certified genomic profiling tests for cancer diagnostics. Tests are performed in their CAP/CLIA certified laboratories in the US and China, with turnaround times of 6-14 days depending on the assay.
2. Biopharma Clinical Trial Support Services: Predicine partners with biopharmaceutical companies to support biomarker-driven drug development, from target discovery through CDx development and commercial launch. Services include comprehensive genomic profiling for clinical trials and companion diagnostic co-development.
3. Companion Diagnostic Development: Predicine is pursuing FDA premarket approval for PredicineCARE as a companion diagnostic for bladder cancer. This regulatory pathway could enable co-development partnerships with pharmaceutical companies for companion diagnostics with novel therapeutics.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Predicine develops and delivers liquid biopsy-based cancer genomic profiling services and assays through its proprietary GeneRADAR wet-lab platform and DeepSEA bioinformatics pipeline, run from CLIA/CAP-certified labs in the United States and China. Its portfolio includes tumor profiling, MRD monitoring, whole-exome, RNA, hereditary, and hematologic cancer assays sold to biopharmaceutical companies for clinical development and to oncologists for treatment-decision support.

Product overview

Predicine is a molecular insight company offering a portfolio of comprehensive genomic profiling assays for precision medicine development. The core offering centers on the GeneRADAR™ liquid biopsy platform that analyzes cell-free DNA (cfDNA) and RNA (cfRNA) from blood or urine samples. The product portfolio includes: PredicineBEACON™ (MRD detection), PredicineATLAS™ (600-gene pan-cancer panel), PredicineCARE™ (200-gene treatment selection panel), PredicineRNA™ (88-gene fusion/splicing panel), PredicineHEME™ (259-gene hematologic malignancies panel), PredicineWES+™ (whole exome sequencing), and PredicineHEREDITARY™ (25-gene hereditary cancer panel). Supporting these is the DeepSEA™ bioinformatics platform for ultra-sensitive variant detection. The company provides end-to-end biopharma clinical research services including biomarker discovery, companion diagnostic co-development, and global clinical trial support across US and China laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• PredicineCARE: 200-gene CLIA-certified cfDNA assay for treatment selection in cancer patients
• PredicineATLAS
• PredicineBEACON
• PredicineRNA
• PredicineHEME
• PredicineWES+
• PredicineHEREDITARY
• GeneRADAR
• DeepSEA
• Generadar

Products and services

• PredicineBEACON

Quantifiable outcome

• Ultra-sensitive MRD detection down to 5 PPM with PredicineBEACON
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Guardant Health: Leading commercial liquid biopsy company offering Guardant360 (ctDNA), Guardant Reveal (MRD), and biopharma CDx services. Directly comparable to Predicine across oncology liquid biopsy, MRD, and pharma trial support.
• Natera: Molecular diagnostics company with Signatera MRD assay and oncology-focused liquid biopsy products. Comparable in MRD sensitivity claims, biopharma trial support, and clinical lab services model.
• Personalis: Genomics company offering NeXT Personal (tumor-informed MRD) and ImmunoID Next platform for biopharma. Closely comparable as a smaller, science-driven liquid biopsy competitor targeting biopharma CDx and oncology trials.
• Caris Life Sciences: Molecular profiling company offering MI Profile, MI Cancer Seek, and biopharma discovery services. Comparable as a multi-omic profiling competitor serving biopharma and oncology clinicians with proprietary assays.
• Tempus AI: Precision medicine company combining NGS profiling (xT, xR) with AI/data analytics for biopharma and providers. Comparable in multi-modal genomic profiling and biopharma clinical trial support services.

Broad incumbents

• Foundation Medicine: Roche subsidiary offering FoundationOne CDx (FDA-approved tissue NGS) and FoundationOne Liquid CDx. The dominant FDA-approved oncology CDx; broader portfolio but directly competes in liquid biopsy and pharma CDx partnerships.
• Exact Sciences: Public diagnostics company with Oncotype, Cologuard, and the recently acquired TheraomiQ liquid biopsy franchise. Comparable as a multi-product oncology diagnostics competitor with biopharma services.
• NeoGenomics: Oncology-focused clinical lab services company offering comprehensive genomic profiling and biopharma trial support. Comparable as a competing oncology reference lab with biopharma/biotech services business.
• Agilent Technologies: Life sciences tools and diagnostics company that acquired Resolution Bioscience for liquid biopsy NGS. Comparable through its cancer genomics business serving biopharma and clinical research customers.

Regional players

• Burning Rock Biotech: China-based liquid biopsy company offering NGS-based cancer panels (e.g., CanPatrol) and pharma services. Directly comparable in product category and is a primary China-region competitor for cross-border trial work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/predicine

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Predicine